University of North Carolina, Chapel Hill
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).
University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.
University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.
Top-decile sponsor footprint
University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,109 total, page 17 of 23
Mindfulness: a Novel Approach for the Management of Diabetes-related Distress
NCT01805245
Error Based Learning for Restoring Gait Symmetry Post-Stroke
NCT01598675
Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques
NCT01495442
Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy
NCT01495845
Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive
NCT01464996
Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects
NCT01489514
Neurostimulation in Temporomandibular Disorders (TMD) Patients
NCT01502709
HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
NCT01474811
Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention
NCT01752504
GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male Subjects
NCT01459315
Trial of Two Techniques to Assess Postoperative Voiding Function
NCT02150083
Comparing Cardiac Output Measurements in Critically Ill Children Using USCOM and Transthoracic ECHO
NCT01460329
Heart-Healthy Lenoir Lifestyle Study
NCT01433484
Improving Care for Patients With High Blood Pressure
NCT01425515
A School Health Center Intervention to Increase Adolescent Vaccination
NCT01595542
Training Dual-Task Walking After Stroke
NCT01568957
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
NCT01492842
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
NCT01364818
Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants
NCT01441206
Enhancement of Connect to Protect® (C2P)
NCT01492816
GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects
NCT01404806
Families and Pediatric Cardiac Surgery Multidisciplinary Teams: How Well Do We Communicate
NCT01371864
Online Study of Colorectal Cancer and Prostate Cancer Screening Decision Making
NCT01558583
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
NCT01394471
Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?
NCT01373125
Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
NCT01373242
Managerial Database II
NCT01322217
Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure
NCT01925703
Pilot Study of Using Copeptin to Predict Response to Tolvaptan
NCT01346072
Improving Money Management Skills for Veterans With Psychiatric Disabilities
NCT01352624
Impact of Black Pepper on Energy Expenditure and Substrate Utilization
NCT01729143
Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina
NCT01544764
Functional Modeling of the Pediatric Airway
NCT01690078
Facebook-based Physical Activity Intervention for Young Adult Cancer Survivors: the FITNET Randomized Pilot Study
NCT01349153
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
NCT01349192
Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.
NCT01320293
Racial Disparity in Barrett's Esophagus
NCT01374074
Tadalafil for Sarcoidosis Associated Pulmonary Hypertension
NCT01324999
A Study of Oxytocin in Children and Adolescents With Autistic Disorder
NCT01308749
Curcumin Pharmacokinetics
NCT01330810
Study of A Cell-Phone System to Improve Health of Youth With Diabetes
NCT02280564
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
NCT01319383
Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk
NCT01245686
A Study Comparing the Interproximal Plaque and Gingivitis Effects of Three Interdental Cleaning Modalities
NCT01307358
The WEIGH Study: Weighing to Improve and Gain Health
NCT01369004
Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study
NCT01284179
Family PALS (PArtners in Lifestyle Support)
NCT01324011
Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1
NCT01241656
Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact
NCT01261481
Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers
NCT01269723
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 111 |
| Phase 2 | 92 |
| Phase 3 | 13 |
| Phase 4 | 56 |
Therapeutic Areas
What is open in the University of North Carolina, Chapel Hill pipeline
108 recruiting of 1,109 indexed (10% open); 881 completed (79%).
Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).
Top condition: Obesity (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of North Carolina, Chapel Hill: open-pipeline peers nationwide
Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,109 trials (± recruiting share)
- University of Florida · 1,106 trials · 15% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Children's Hospitals and Clinics of Minnesota · 10% recruiting · 31 trials
- Cytokinetics · 10% recruiting · 31 trials
- Sanofi · 10% recruiting · 713 trials
- Ohio University · 10% recruiting · 51 trials
Related
What to do with this University of North Carolina, Chapel Hill page
1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.
- 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.